Interferon Regulatory Factor 5 Mediates Lipopolysaccharide-Induced Neuroinflammation.
IRF5
intracerebroventricular
lipopolysaccharide
neuroinflammation
siRNA interfering
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
08
2020
accepted:
26
10
2020
entrez:
28
12
2020
pubmed:
29
12
2020
medline:
17
6
2021
Statut:
epublish
Résumé
Activated microglia play a vital role in neuroinflammation in the central nervous system (CNS), which is associated with the pathogenesis and the progression of neurological diseases. Interferon regulatory factor 5 (IRF5) has been well established participating in inflammatory responses and is highly expressed in M1 macrophage in the periphery, the role of which in the CNS remains elusive. Lipopolysaccharide (LPS) was employed to induce neuroinflammation. Down-regulation of IRF5 in C57/BL6 mice and BV2 microglial cells were achieved by IRF5 siRNA transfection. The levels of pro-inflammatory cytokines were evaluated by ELISA and quantitative real-time PCR. The expression levels of IRF5 were examined by immunofluorescence and Western blot. LPS induced significantly elevated expression of IRF5 in mouse brain, which co-localized with CD11b-positive microglia. Down-regulation of IRF5 quenched the pro-inflammatory responses. The levels of pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 were up-regulated at 4 h after LPS treatment, which were significantly down-regulated with the knockdown of IRF5. LPS-induced pro-inflammatory responses were transient, which were comparable to control group at 24 h after LPS treatment. However, LPS did not up-regulate the expression of IRF5 in BV2 microglial cells, indicating that LPS-induced inflammation in BV2 cells does not involve IRF5 signaling. IRF5 mediates the inflammatory responses in the CNS, which might serve as a therapeutic target for CNS inflammatory diseases. LPS-induced inflammation does not involve IRF5 signaling in BV2 microglia.
Sections du résumé
Background
Activated microglia play a vital role in neuroinflammation in the central nervous system (CNS), which is associated with the pathogenesis and the progression of neurological diseases. Interferon regulatory factor 5 (IRF5) has been well established participating in inflammatory responses and is highly expressed in M1 macrophage in the periphery, the role of which in the CNS remains elusive.
Methods
Lipopolysaccharide (LPS) was employed to induce neuroinflammation. Down-regulation of IRF5 in C57/BL6 mice and BV2 microglial cells were achieved by IRF5 siRNA transfection. The levels of pro-inflammatory cytokines were evaluated by ELISA and quantitative real-time PCR. The expression levels of IRF5 were examined by immunofluorescence and Western blot.
Results
LPS induced significantly elevated expression of IRF5 in mouse brain, which co-localized with CD11b-positive microglia. Down-regulation of IRF5 quenched the pro-inflammatory responses. The levels of pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 were up-regulated at 4 h after LPS treatment, which were significantly down-regulated with the knockdown of IRF5. LPS-induced pro-inflammatory responses were transient, which were comparable to control group at 24 h after LPS treatment. However, LPS did not up-regulate the expression of IRF5 in BV2 microglial cells, indicating that LPS-induced inflammation in BV2 cells does not involve IRF5 signaling.
Conclusions
IRF5 mediates the inflammatory responses in the CNS, which might serve as a therapeutic target for CNS inflammatory diseases. LPS-induced inflammation does not involve IRF5 signaling in BV2 microglia.
Identifiants
pubmed: 33362784
doi: 10.3389/fimmu.2020.600479
pmc: PMC7755991
doi:
Substances chimiques
Cytokines
0
Interferon Regulatory Factors
0
Irf5 protein, mouse
0
Lipopolysaccharides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
600479Informations de copyright
Copyright © 2020 Fan, Zhao, Zhu, Li, Liu, Yan, Tian, Chen and Zhang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Glia. 2016 Feb;64(2):300-16
pubmed: 26470014
Annu Rev Neurosci. 1999;22:219-40
pubmed: 10202538
J Physiol Sci. 2018 Nov;68(6):881
pubmed: 29679307
Stroke. 2012 Nov;43(11):3063-70
pubmed: 22933588
Nat Rev Immunol. 2008 Dec;8(12):958-69
pubmed: 19029990
Nature. 2005 Mar 10;434(7030):243-9
pubmed: 15665823
J Immunol. 2018 May 1;200(9):3218-3230
pubmed: 29563175
PLoS One. 2012;7(3):e33098
pubmed: 22412986
ALTEX. 2009;26(2):83-94
pubmed: 19565166
Eur J Neurosci. 2018 Jan;47(2):140-149
pubmed: 29131464
J Neuropathol Exp Neurol. 1998 Mar;57(3):257-67
pubmed: 9600218
Nucleic Acids Res. 2011 Sep 1;39(16):7300-7
pubmed: 21596780
PLoS One. 2015 Mar 26;10(3):e0121117
pubmed: 25811458
Behav Brain Res. 2011 Apr 15;218(2):267-79
pubmed: 21070822
J Neuroimmunol. 2008 Dec 15;205(1-2):51-6
pubmed: 18838174
Mediators Inflamm. 2013;2013:731023
pubmed: 24379524
Glia. 2013 Jan;61(1):71-90
pubmed: 22674585
Nat Immunol. 2011 Mar;12(3):231-8
pubmed: 21240265
Nature. 2002 Jul 11;418(6894):244-51
pubmed: 12110901
J Interferon Cytokine Res. 2002 Jan;22(1):59-71
pubmed: 11846976
Proc Natl Acad Sci U S A. 2020 Jan 21;117(3):1742-1752
pubmed: 31892541
Brain Res Brain Res Rev. 2002 Jun;39(1):55-73
pubmed: 12086708
Eur J Neurosci. 2016 Jun;43(12):1674-82
pubmed: 27061018
J Neuroinflammation. 2016 Jul 11;13(1):182
pubmed: 27400875
Annu Rev Immunol. 2001;19:623-55
pubmed: 11244049
Nat Commun. 2014 May 13;5:3771
pubmed: 24818655
Annu Rev Biophys. 2013;42:217-39
pubmed: 23654304
Nat Neurosci. 2005 Jun;8(6):752-8
pubmed: 15895084
Biochim Biophys Acta. 2015 Feb;1852(2):365-78
pubmed: 24807060
Nat Immunol. 2006 Jul;7(7):773-82
pubmed: 16767092